Mersana Therapeutics (MRSN) Competitors $0.37 -0.02 (-5.13%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. SOPH, VYGR, YMAB, CRGX, SCPH, NBTX, DMAC, ELDN, INBX, and PRQRShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), CARGO Therapeutics (CRGX), scPharmaceuticals (SCPH), Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), Eledon Pharmaceuticals (ELDN), Inhibrx (INBX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. SOPHiA GENETICS Voyager Therapeutics Y-mAbs Therapeutics CARGO Therapeutics scPharmaceuticals Nanobiotix DiaMedica Therapeutics Eledon Pharmaceuticals Inhibrx ProQR Therapeutics Mersana Therapeutics (NASDAQ:MRSN) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Does the media prefer MRSN or SOPH? In the previous week, Mersana Therapeutics had 24 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 24 mentions for Mersana Therapeutics and 0 mentions for SOPHiA GENETICS. Mersana Therapeutics' average media sentiment score of 0.39 beat SOPHiA GENETICS's score of 0.00 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mersana Therapeutics Neutral SOPHiA GENETICS Neutral Do insiders and institutionals hold more shares of MRSN or SOPH? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is MRSN or SOPH more profitable? SOPHiA GENETICS has a net margin of -110.71% compared to Mersana Therapeutics' net margin of -214.20%. SOPHiA GENETICS's return on equity of -55.06% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-214.20% -401.37% -38.61% SOPHiA GENETICS -110.71%-55.06%-38.33% Do analysts rate MRSN or SOPH? Mersana Therapeutics currently has a consensus price target of $5.20, suggesting a potential upside of 1,305.41%. SOPHiA GENETICS has a consensus price target of $6.80, suggesting a potential upside of 130.51%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has higher earnings and valuation, MRSN or SOPH? SOPHiA GENETICS has higher revenue and earnings than Mersana Therapeutics. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M1.14-$171.67M-$0.59-0.63SOPHiA GENETICS$67.17M2.93-$78.98M-$1.00-2.95 Which has more volatility & risk, MRSN or SOPH? Mersana Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Does the MarketBeat Community believe in MRSN or SOPH? Mersana Therapeutics received 237 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 66.49% of users gave Mersana Therapeutics an outperform vote. CompanyUnderperformOutperformMersana TherapeuticsOutperform Votes25666.49% Underperform Votes12933.51% SOPHiA GENETICSOutperform Votes1970.37% Underperform Votes829.63% SummaryMersana Therapeutics beats SOPHiA GENETICS on 12 of the 19 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.86M$6.54B$5.40B$8.47BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.609.1226.7519.95Price / Sales1.14252.31393.46114.60Price / CashN/A65.8538.2534.62Price / Book1.196.486.834.58Net Income-$171.67M$143.78M$3.22B$248.19M7 Day Performance-2.63%4.80%5.26%2.14%1 Month Performance13.18%9.37%13.27%16.20%1 Year Performance-85.88%-1.19%17.58%7.87% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics3.8469 of 5 stars$0.37-5.1%$5.20+1,305.4%-85.9%$45.86M$40.50M-0.60150Earnings ReportAnalyst RevisionGap DownSOPHSOPHiA GENETICS1.8276 of 5 stars$2.86-3.4%$6.80+137.8%-36.7%$190.73M$67.17M-2.62520Gap UpVYGRVoyager Therapeutics4.6952 of 5 stars$3.43+3.9%$13.39+290.4%-59.8%$189.80M$66.96M4.83100Gap UpYMABY-mAbs Therapeutics3.5045 of 5 stars$4.17+1.7%$16.60+298.1%-64.2%$188.83M$87.69M-7.72150Analyst ForecastAnalyst RevisionCRGXCARGO Therapeutics2.2313 of 5 stars$4.09-0.7%$15.00+266.7%-79.9%$188.59MN/A-0.96116Positive NewsSCPHscPharmaceuticals4.1728 of 5 stars$3.52+9.3%$14.00+297.7%-18.6%$185.83M$41.98M-1.8530Earnings ReportAnalyst RevisionHigh Trading VolumeNBTXNanobiotix1.7289 of 5 stars$3.94+2.1%$8.00+103.0%-46.1%$185.70M$-11,609,000.000.00100DMACDiaMedica Therapeutics1.5038 of 5 stars$4.27+1.7%$8.00+87.4%+35.3%$183.11MN/A-7.6220News CoverageAnalyst RevisionGap UpHigh Trading VolumeELDNEledon Pharmaceuticals2.1861 of 5 stars$3.04+5.9%$12.50+311.2%-1.9%$182.04MN/A-1.5110News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpINBXInhibrx1.9416 of 5 stars$12.47+1.1%N/A-62.1%$180.52M$200,000.000.11166Earnings ReportPRQRProQR Therapeutics3.0806 of 5 stars$1.71+5.6%$8.00+367.8%-8.3%$179.91M$18.97M-5.34180 Related Companies and Tools Related Companies SOPH Competitors VYGR Competitors YMAB Competitors CRGX Competitors SCPH Competitors NBTX Competitors DMAC Competitors ELDN Competitors INBX Competitors PRQR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRSN Stock Free MRSN Stock Alerts